Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Spray Live Attenuated Influenza Vaccine in Adults 18-59 Years
NCT07133802Phase 3Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing Nasal Spray Live Attenuated Influenza Vaccine with Placebo (2 arms). Primary endpoint: Protective Efficacy. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
Ganwu
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07133802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133802.